What Is E-64? Definition and What Research Reports

Definition

E-64 is a small, peptide-derived molecule that acts as an irreversible inhibitor of cysteine proteases — the family of protein-cutting enzymes that includes papain, the lysosomal cathepsins (B, H and L) and, in cell systems, the calpains. It works covalently: an epoxide group reacts with the thiol of the enzyme's catalytic cysteine, permanently disabling that enzyme molecule. In practical terms, E-64 is a reagent rather than a therapeutic. It appears in the literature as a tool used to switch off a class of enzymes so that researchers can observe what changes in a cell, tissue, organism or fermentation broth when those enzymes are no longer active.

What class of molecule is it, and where does it come from?

E-64 belongs to the epoxysuccinyl peptide inhibitors. Its structure pairs an epoxysuccinyl "warhead" with a short peptide-like arm — a leucine amide linked to a guanidinobutyl group — which is why it is often grouped with peptide-based chemical probes even though it is not a signalling peptide. E-64 was originally characterised as a microbial natural product of fungal origin, and its scaffold has since been reproduced and diversified synthetically. A 2025 report in Nature Chemical Biology described an enzymatic combinatorial synthesis approach for producing E-64 and related cysteine protease inhibitors (PMID 40346252).

How the Term Is Used in Peptide and Protein Research

Within peptide and protein science, "E-64" is usually shorthand for one of three things:

• A protease inhibitor in buffers and media. Because cysteine proteases degrade peptides and recombinant proteins during extraction or culture, E-64 is added to suppress that degradation. A 2024 study in European Journal of Protistology examined the use of the E-64 cysteine protease inhibitor for recombinant protein production in Tetrahymena thermophila (PMID 38703600).
• A pharmacological probe. When investigators want to test whether cysteine proteases are required for a biological process, E-64 is applied and the outcome is compared with untreated controls.
• A reference compound for a chemical class. Newer epoxysuccinyl inhibitors are frequently benchmarked against E-64, and derivatives such as E-64c and the cell-permeable ester E-64-d carry the same stem name.

E-64 versus E-64-d

The two names are not interchangeable. E-64 itself is poorly cell-permeable and is often used extracellularly or in lysates, while E-64-d is a membrane-permeable ester derivative described in the literature as a selective calpain inhibitor; a 2015 paper in BioMed Research International evaluated the therapeutic efficacy of E-64-d in experimental acute spinal cord injury (PMID 26240815). Readers scanning abstracts should note which form a paper used before comparing results.

What the Published Literature Reports

The E-64 literature is dominated by in vitro and animal work, and it spans several unrelated fields. The common thread is that E-64 was used to ask whether a given cysteine protease was necessary for something to happen.

Parasitology and infection biology

Several studies applied E-64 to parasites in culture. A 2014 paper in PLoS One reported that inhibition of cathepsin B by E-64 induced oxidative stress and apoptosis in a filarial parasite (PMID 24667798), and a separate 2014 report in Revista do Instituto de Medicina Tropical de São Paulo described in vitro antigiardial activity of the cysteine protease inhibitor E-64 (PMID 24553607). In fish parasitology, a 2024 study combined single-cell transcriptome profiles with E-64 inhibitor data and concluded that cysteine proteases played an essential role in the ontogeny of Ichthyophthirius multifiliis (PMID 39442737). On the virology side, a 2021 paper in Bioorganic & Medicinal Chemistry reported that the small molecule inhibitor E-64 exhibited activity against the African swine fever virus protein pS273R (PMID 33607487).

Organ injury and cardiovascular-renal models

E-64 has also been used to test the calpain and cathepsin hypotheses of tissue injury. A 2005 study in Biochemical Pharmacology examined inhibitors of calpain activation — PD150606 and E-64 — in the context of renal ischaemia-reperfusion injury (PMID 15763548). A 2016 paper in Physiological Reports investigated chronic cathepsin inhibition by E-64 in Dahl salt-sensitive rats (PMID 27597769). These were animal and mechanistic investigations; neither is a human clinical trial, and E-64 is not an approved human medicine.

Reproductive biology and biotechnology

In reproductive science, a 2022 study in Genes assessed the effect of E-64 supplementation during in vitro maturation on the developmental competence of bovine oocytes recovered by ovum pick-up (PMID 35205369), and a 2017 paper in Reproduction, Fertility and Development reported that papain and its inhibitor E-64 reduced camelid semen viscosity without impairing sperm function and improved post-thaw motility rates (PMID 27156102). In that last setting, E-64 was used to stop an added enzyme once it had done its job — an illustration of how the compound functions as a switch in a workflow rather than as a treatment.

Representative Studies at a Glance

Tolerability in Research Models: What Studies Report

Published E-64 work is preclinical, and the papers listed here describe experiments in cells, parasites, gametes and laboratory animals rather than tolerability data in people. One reproductive study noted that treatment with papain and E-64 reduced camelid semen viscosity without impairing sperm function (PMID 27156102), and the chronic-dosing question in rodents was addressed in a study of chronic cathepsin inhibition by E-64 in Dahl salt-sensitive rats (PMID 27597769). No human safety profile, approved indication or clinical dosing framework for E-64 exists in the sources reviewed here, and none is described on this page.

What E-64 Is Not

• It is not a peptide hormone, growth-factor analogue or secretagogue.
• It is not an approved human or veterinary medicine; it appears in the literature as a research chemical and laboratory reagent.
• It is not selective for a single enzyme — it acts broadly across many cysteine proteases, which is why abstracts often pair it with more selective probes to interpret results.

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified healthcare professional about any health question or before acting on anything described in the scientific literature. The entry summarises what published studies reported and does not describe protocols, quantities or applications for individuals.

References

• Enzymatic combinatorial synthesis of E-64 and related cysteine protease inhibitors (Nature Chemical Biology, 2025)
• Use of E-64 cysteine protease inhibitor for the recombinant protein production in Tetrahymena thermophila (European Journal of Protistology, 2024)
• Single-cell transcriptome profiles and E-64 inhibitor data reveal the essential role of cysteine proteases in the ontogeny of Ichthyophthirius multifiliis (Fish & Shellfish Immunology, 2024)
• Effect of E-64 Supplementation during In Vitro Maturation on the Developmental Competence of Bovine OPU-Derived Oocytes (Genes, 2022)
• Small molecule inhibitor E-64 exhibiting the activity against African swine fever virus pS273R (Bioorganic & Medicinal Chemistry, 2021)
• Papain and its inhibitor E-64 reduce camelid semen viscosity without impairing sperm function and improve post-thaw motility rates (Reproduction, Fertility and Development, 2017)
• Chronic cathepsin inhibition by E-64 in Dahl salt-sensitive rats (Physiological Reports, 2016)
• Therapeutic Efficacy of E-64-d, a Selective Calpain Inhibitor, in Experimental Acute Spinal Cord Injury (BioMed Research International, 2015)
• Inhibition of cathepsin B by E-64 induces oxidative stress and apoptosis in filarial parasite (PLoS One, 2014)
• In vitro antigiardial activity of the cysteine protease inhibitor E-64 (Revista do Instituto de Medicina Tropical de São Paulo, 2014)
• Inhibitors of calpain activation (PD150606 and E-64) and renal ischemia-reperfusion injury (Biochemical Pharmacology, 2005)